Closing Gaps in HAE Management: Understanding What Control Means for Your HAE Patients

This symposium and its associated materials were funded by KalVista Pharmaceuticals.

For healthcare professionals only. The views expressed are those of the named speakers.

This symposium held during the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, explores evolving definitions of disease control in hereditary angioedema (HAE) and the pivotal role of timely on-demand treatment. Moderated by Douglas Jones, this interactive panel features insights from Stephen Betschel, Thomas Buttgereit, and Sinisa Savic, who together examine guideline recommendations, patient-reported outcomes, and clinical perspectives on early intervention.

Supported by real-world data, the panel reviews challenges in treatment adherence and the psychological burden experienced by patients with HAE. Through integrated video testimony and discussion, this session captures the diverse and often unmet needs of people living with HAE, highlighting actionable strategies to empower patient-centred care and improve disease control outcomes.

1. Global Allergy Immune Network, USA
2. Charité – Universitätsmedizin Berlin, Germany
3. St Michael’s Hospital, Toronto, Canada
4. Leeds Teaching Hospitals NHS Trust, Leeds, UK